Close Menu

Hundreds to Go

Pharmaceutical company Sanofi-Aventis is eliminating “hundreds of jobs,” reports Ed Silverman at Pharmalot. The cuts come in the wake of Sanofi’s acquisition of Genzyme, he say, adding that some R&D operations will be shuffled between its New Jersey and Massachusetts sites, and that there will be layoffs in sales, particularly in the cardiovascular and oncology groups.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.